Supernus stock surges after ADHD-drug study results

/ / News

Supernus Pharmaceuticals Inc. shares jumped more than 20% in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hyperactivity disorder, or ADHD. Supernus announced Tuesday afternoon that a phase 3 study of the drug, known as SPN-812, on adults achieved its targeted endpoint. The Food and Drug Administration is already considering the drug for use in children ages 6 to 17, and Supernus plans to ask for the drug to be considered for adults as well if it is approved by the FDA. Shares leapt more than 40% in trades immediately following the end of an after-hours trading halt Tuesday afternoon, but settled down to gains closer to 20% later in the extended session.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.